Biomanufacturing Trends In 2014
The drug development industry is motivated to invest in developing biopharmaceuticals as a form of pipeline security because these products have demonstrated profitability. The practice of partnering with or acquiring biopharmaceutical companies is mirrored in the results of the Nice Insight Pharmaceutical and Biotechnology Outsourcing survey, where 73 percent of respondents stated the company they work for engages in the development of biologics-based therapeutics. These respondents will spend more than half of their outsourcing budget on the development of biologics — 57 percent compared to 43 percent of the outsourcing budget spent on conventional therapeutics.
The latest industry trends and proprietary data from Nice Insight survey results.